Policy Filings and Resources

CTA Comments on Sen. Cassidy's Health Data Privacy RFI

CTA comments on Sen. Cassidy's request for information on health data privacy

CTA Comments to FTC/DOJ on Changes to HSR Merger Review Form

Comments to the Federal Trade Commission (FTC) and U.S. Department of Justice

CTA Comments on Sen. Cassidy's Artificial Intelligence Whitepaper

CTA Comments on Sen. Bill Cassidy's whitepaper entitled Exploring Congress’ Framework for the Future of AI: The Oversight and Legislative Role of Congress Over the Integration of Artificial Intelligence in Health, Education, and Labor.

Testimony of Deena Ghazarian to Energy and Commerce Committee

Mapping America’s Supply Chains: Solutions to Unleash Innovation, Boost Economic Resilience, and Beat China

CTA Comments to FTC/DOJ on Draft Merger Guidelines

Comments to the Federal Trade Commission (FTC) and U.S. Department of Justice

CTA Comments on CY 2024 Medicare Physician Fee Schedule Proposed Rule

CTA President and CEO Gary Shapiro's Letter to President Biden Re: China Tariffs

CTA Comments to Federal Communications Commission on Access to Videoconferencing

Comments to Federal Communications Commission (FCC)

CTA Comments on Advancing Inclusive, Worker-centered Trade Policy

Comments to the U.S. Trade Representative

CTA Joins Amicus Brief in Coinbase v. SEC

CTA Comments to Federal Trade Commission on Health Breach Notification Rule

Comments to Federal Trade Commission

CTA Comments on the proposed changes to Antidumping and Countervailing Duty Laws

Comments to the Department of Commerce

CTA One-Pager on AM Radio Mandate

CTA Comments on Negative Option Rule

Comments to Federal Trade Commission (FTC)

CTA Comments on Business Practices of Cloud Computing Providers

Comments to Federal Trade Commission (FTC)

CTA Comments on U.S. Patent and Trademark Office's Advanced Notice of Proposed Rulemaking

CTA response to the Patent and Trademark Office

CTA Letter in Support of Direct Capital Access Act

Letter to U.S. Senate Committee on Commerce, Science, and Transportation and U.S. House Committee on Transportation and Infrastructure

CTA AI Response Letter to Senators Hickenlooper and Blackburn

CTA AI Response Letter to Senators Hickenlooper and Blackburn.

CTA Letter to Congress Following AM Radio Hearing on June 6, 2023

Letter to Subcommittee on Communications & Technology and House Energy & Commerce Committee Chair and Ranking Member.

CTA Comments on the proposed updates to Circular A-4, "Regulatory Analysis"

Comments to the Office of Management and Budget

CTA Letter to Congress Urging Opposition to AM Radio Mandate for Autos

Letter to Subcommittee on Communications & Technology and House Energy & Commerce Committee Chair and Ranking Member.

CTA Comments on the Americas Partnership for Economic Prosperity

Comments to the Government of Canada

CTA Testimony on Impersonation Fraud

Testimony to Federal Trade Commission on government and business impersonation fraud

CTA Comments on Metaverse and Related Public Policy Considerations

Comments to European Commission 

CTA Comments on Hearing Aid Compatibility Task Force's Final Report and Recommendation

Comments to Federal Communications Commission (FCC)

CTA Comments on Non-Compete Proposed Rule

Comments to Federal Trade Commission (FTC)

CTA Comments on National Spectrum Strategy

Comments to National Telecommunications and Information Administration (NTIA)

CTA Letter Opposing FTC FY24 Budget Request

Letter to House Energy and Commerce Committee Chair and Ranking Member

CTA Statement for the Record for the Respective Hearings on the 2023 U.S. Trade Policy Agenda

Statement submitted to the Senate Finance and House Ways and Means Committees

CTA Comments on Telemedicine Prescribing of Buprenorphine

CTA submitted comments to the Drug Enforcement Agency in response to the DEA proposed rule Expansion of Induction of Buprenorphine via Telemedicine Encounter.

CTA Comments on Telemedicine Prescribing of Controlled Substances

CTA submitted comments to the Drug Enforcement Agency in response to the DEA proposed rule Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation.

CTA Letter Opposing FTC FY24 Budget Request

Letter to House and Senate Appropriations Committees

CTA Comments on Senate Health, Education, Labor & Pensions Committee Request for Input on Health Care Workforce Shortages

Comments to Senate Health, Education, Labor & Pensions Committee

CTA Comments on Button/Coin Cell Batteries

Comments to U.S. Consumer Product Safety Commission (CPSC)

CTA Comments on Privacy, Equity and Civil Rights

Comments to National Telecommunications and Information Administration (NTIA)

Jeff Zients Appointment to Chief of Staff

Letter to White House

CTA Health Priorities for 118th Congress

Letter to Congressional Leadership

Implementation of Additional Export Controls

Letter to the U.S. Department of Commerce 

National Economic Council Vacancy

CTA Coalition Letter to the White House 

Four-Year Review of Actions Taken in the Section 301 Investigation

Comments to the United States Trade Representative  

CTA Letter on DOJ and FTC Merger Guidelines

Energy Labeling Rule

Comments to the Federal Trade Commission